Bio Break: Real-Time Imaging for Targeted Drug Delivery
In this episode of Bio Break, Nick and Joris discuss the fascinating world of real-time imaging for targeted drug delivery. When delivering drugs to precise locations in the body, how do we ensure they reach the right spot? The answer lies in medical imaging technologies such as MRI, CT, and ultrasound, which play a crucial role in guiding complex drug delivery devices.
Nick starts by asking how imaging technologies help visualize drug targeting during delivery. Joris explains that MRI (Magnetic Resonance Imaging), CT (Computed Tomography), and ultrasound are the three most commonly used imaging techniques. Each has its advantages and limitations depending on the application.
- MRI offers exceptional resolution and is ideal for deep-tissue targeting, such as brain delivery for conditions like Parkinson’s disease. However, intraoperative MRI machines are less accessible in hospitals, making their real-time use challenging.
- CT scanning is more widely available and excellent for bone-related targeting, such as spinal drug delivery. While it has slightly lower resolution than MRI, it is a practical and widely adopted solution in medical settings.
- Ultrasound is the most real-time imaging method and is commonly used for nerve blocks and pain management. However, it has depth limitations and is ineffective for regions behind bone, such as the brain.
Nick and Joris also discuss the future of medical imaging in drug delivery. With advancements in 3D imaging and computational modeling, physicians will soon have better spatial awareness of the drug delivery process, improving precision and patient outcomes.
As medical imaging evolves, AI-driven technologies and 3D imaging integration will revolutionize precision drug delivery, making it more efficient and accessible.
Real-Time Imaging for Targeted Drug Delivery
Related Resources
Ariana and Mark walk through what separates a clinical prototype from a proof-of-concept build, what determines how much testing and documentation you actually need, and where the regulatory line between significant risk and non-significant risk falls.
In this episode of Bio Break, Nick walks through both patent types after receiving two of his own in the mail, one of each, from the USPTO.
Scott Phillips sits down with Mickey Urdea to examine what actually distinguishes companies that reach commercial outcomes from those that do not.
Nigel Syrotuck breaks down the realistic medical device V&V cost and schedule for terminally sterilized devices, picking up after design freeze and walking through each major phase of the process.